Antiepileptic potential of ganaxolone
Abstract
References
Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: A systematic review. Pharmacoeconomics 2008; 26(6): 463−76.
Jankovic SM, Ignjatovic Ristic D. Is bioavailability altered in generic versus brand anticonvulsants. Expert Opin Drug Metab Toxicol 2015; 11(3): 329−32.
Jankovic S, Ilickovic I. The preclinical discovery and development of ezogabine for the treatment of epilepsy. Expert Opin Drug Discov 2013; 8(11): 1429−37.
Jankovic SM, Dostic M. Choice of antiepileptic drugs for the el-derly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol 2012; 8(1): 81−91.
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47(7): 1094−120.
Milovanovic JR, Jankovic SM. Factors influencing carbamazepine pharmacokinetics in children and adults: Population pharma-cokinetic analysis. Int J Clin Pharmacol Ther 2011; 49(7): 428−36.
Jankovic SM, Milovanovic JR, Jankovic S. Factors influencing val-proate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther 2010; 48(11): 767−75.
Sánchez-Álvarez JC, Mauri-Llerda JA, Gil-Nagel A, Casas-Fernández C, Salas-Puig J, Lahuerta J, et al. Consensus-recommended diagnostic and therapeutic guidelines for drug-resistant epilepsy in Spain (Consenso RATE-España). Neurologia 2012; 27(8): 481−90.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342(5): 314−9.
Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr 2013; 50(11): 1033−40.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen HW, Mathern G, et al. Definition of drug resistant epilepsy: consensus pro-posal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069−77.
Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ 2014; 348: g254.
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010; 51(1): 7−26.
Abraham S, Shaju M. Innovations in epilepsy management: An overview. J Pharm Pharm Sci 2013; 16(4): 564−76.
Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009; 61(2): 197−216.
Reddy DS. Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113−37.
Benjamin M. Small Biotech Companies Target CNS Disorders. Psychiatric Times [cited 1998 May 1]. Available from: http://www.psychiatrictimes.com/articles/small-biotech-companies-target-cns-disorders
Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007; 4(1): 102−5.
Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69(3): 273−94.
Sigma-Aldrich. G7795 Sigma, Ganaxolone. [accessed 2014 December 28]. Available from: http://www.sigmaaldrich.com/catalog/product/sigma/g7795?lang=en®ion=SX
Shaw K, Zhang M. Generic Ganaxolone formulations and me-thods for the making and use thereof. EP1959966A2. 2008.
Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric ac-id-gated Cl- currents. Mol Pharmacol 1991; 39(6): 691−6.
Belelli D, Lambert JJ. Neurosteroids: Endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005; 6(7): 565−75.
Pinna G, Uzunova V, Matsumoto K, Puia G, Mienville JM, Costa E, et al. Brain allopregnanolone regulates the potency of the GA-BA(A) receptor agonist muscimol. Neuropharmacology 2000; 39(3): 440−8.
Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997; 280(3): 1284−95.
Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006; 444(7118): 486−9.
Gasior M, Carter RB, Goldberg SR, Witkin JM. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 1997; 282(2): 543−53.
Gasior M, Ungard JT, Beekman M, Carter RB, Witkin JM. Acute and chronic effects of the synthetic neuroactive steroid, ga-naxolone, against the convulsive and lethal effects of pentyle-netetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology 2000; 39(7): 1184−96.
Kaminski RM, Gasior M, Carter RB, Witkin JM. Protective effi-cacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur J Pharmacol 2003; 474(2−3): 217−22.
Mares P, Stehlíková M. Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats. Neu-rosci Lett 2010; 469(3): 396−9.
Liptáková S, Velísek L, Velísková J, Moshé SL. Effect of ganax-olone on flurothyl seizures in developing rats. Epilepsia 2000; 41(7): 788−93.
Yum M, Lee M, Ko T, Velíšek L. A potential effect of ganax-olone in an animal model of infantile spasms. Epilepsy Res 2014; 108(9): 1492−500.
Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004; 45(7): 864−7.
Reddy DS, Rogawski MA. Chronic treatment with the neuroac-tive steroid ganaxolone in the rat induces anticonvulsant toler-ance to diazepam but not to itself. J Pharmacol Exp Ther 2000; 295(3): 1241−8.
Reddy DS, Rogawski MA. Ganaxolone suppression of behavior-al and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res 2010; 89(2−3): 254−60.
Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000; 294(3): 909−15.
Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009; 6(2): 392−401.
Snead O. Ganaxolone, a selective, high-affinity steroid modula-tor of the?-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol 1998; 44(4): 688−91.
Citraro R, Russo E, Di Paola ED, Ibbadu GF, Gratteri S, Marra R, et al. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized ab-sence epilepsy. Neuropharmacology 2006; 50(8): 1059−71.
Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, et al. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther 1998; 284(3): 868−77.
Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology (Berl) 2000; 148(4): 336−43.
Vanover KE, Suruki M, Huber M, Wilent WB, Carter RB. Neu-roactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice. Psycho-pharmacology (Berl) 2000; 149(3): 269−76.
Belelli D, Herd MB. The contraceptive agent Provera enhances GABA(A) receptor-mediated inhibitory neurotransmission in the rat hippocampus: evidence for endogenous neurosteroids. J Neurosci 2003; 23(31): 10013−20.
Robichaud M, Debonnel G. Allopregnanolone and ganaxolone in-crease the firing activity of dorsal raphe nucleus serotonergic neurons in female rats. Int J Neuropsychopharmacol 2006; 9(2): 191−200.
Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine ste-reospecifically and selectively increase brain neurosteroid con-tent at doses that are inactive on 5-HT reuptake. Psychophar-macology (Berl) 2006; 186(3): 362−72.
Ramaker MJ, Ford MM, Fretwell AM, Finn DA. Alteration of ethanol drinking in mice via modulation of the GABA(A) re-ceptor with ganaxolone, finasteride, and gaboxadol. Alcohol Clin Exp Res 2011; 35(11): 1994−2007.
Besheer J, Lindsay TG, Buckley TO, Hodge CW, Morrow LA. Preg-nenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats. Alcohol Clin Exp Res 2010; 34(12): 2044−52.
Ramaker MJ, Strong MN, Ford MM, Finn DA. Effect of ganax-olone and THIP on operant and limited-access ethanol self-administration. Neuropharmacology 2012; 63(4): 555−64.
Ramaker MJ, Strong-Kaufman MN, Ford MM, Phillips TJ, Finn DA. Effect ofnucleus accumbens shell infusions of ganaxolone or gaboxadol on ethanol consumption in mice. Psycho-pharmacology (Berl) 2015; 232(8): 1415−26.
Ramaker MJ, Ford MM, Phillips TJ, Finn DA. Differences in the reinstatement ofethanol seeking with ganaxolone and gabox-adol. Neuroscience 2014; 272: 180−7.
Heulens I, Hulst CD, Van DD, De DP, Kooy FR. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res 2012; 229(1): 244−9.
Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 2008; 57(2): 410−20.
Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, et al. Decreased cerebrospinal fluid allopregnano-lone levels in women with posttraumatic stress disorder. Biol Psychiatry 2006; 60(7): 704−13.
Pinna G, Rasmusson AM. Ganaxolone improves behavioral def-icits in a mousemodel of post-traumatic stress disorder. Front Cell Neurosci 2014; 8: 256.
Pinna G. Targeting neurosteroidogenesis as therapy for PTSD. Front Pharmacol 2014; 4: 166.
Asiedu MN, Mejia G, Ossipov MK, Malan PT, Kaila K, Price TJ. Modulation of spinal GABAergic analgesia by inhibition of chloride extrusion capacity in mice. J Pain 2012; 13(6): 546−54.
Paul AM, Branton WG, Walsh JG, Polyak MJ, Lu JQ, Baker GB, et al. GABA transport and neuroinflammation are coupled in multiple sclerosis: Regulation of the GABA transporter-2 by ganaxolone. Neuroscience 2014; 273: 24−38.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White SH. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010; 92(2−3): 89−124.
Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Ini-tial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997; 38(9): 1026−31.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White SH. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013; 103(1): 2−30.
Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, et al. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganax-olone Presurgical Study Group. Epilepsia 2000; 41(9): 1187−94.
Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, et al Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res 2000; 42(2−3): 133−9.
Pieribone VA, Tsai J, Soufflet C, Rey E, Shaw K, Giller E, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 2007; 48(10): 1870−4.
McAuley JW, Reeves Al, Flyak J, Monaghan EP, Data J. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: Clinical experience in two patients. Epilepsia 2001; 42(Suppl 7): 85.
Reddy DS, Rogawski MA. Neurosteroids: Endogenous Regula-tors of SeizureSusceptibility and Role in the Treatment of Epi-lepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilep-sies. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
ClinicalTrials.gov. Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures, With Long-term Open-label Extension. Identifier: NCT01963208. Availa-ble from: https://clinicaltrials.gov/ct2/show/NCT01963208?term=ganaxolone&rank=4
Marinus pharmaceuticals provides business update and reports third quarter 2014 financial results. 2014. Radnor, pa., nov. 13, (globe newswire). Available from: http://ir.marinuspharma.com/releasedetail.cfm?releaseid=882728
Sánchez-Alvarez JC, Serrano-Castro P, Cañadillas-Hidalgo F. Re-fractory epilepsy in adults. Rev Neurol 2002; 35(10): 931−53.